Iversun is a prescription antiparasitic medication containing ivermectin, developed for the targeted treatment of parasitic infections in adults. It works by binding to glutamate-gated chloride ion channels in nerve and muscle cells of parasites, leading to increased cell permeability, paralysis, and eventual death of the organism. This mechanism allows for effective clearance of a range of nematode and arthropod infestations with a well-established safety profile when used as directed under medical supervision. Iversun is formulated for oral administration and is indicated only after confirmed diagnosis and professional consultation.

Features

• Active ingredient: Ivermectin 3 mg tablets
• Formulation: Oral tablet, film-coated for ease of swallowing
• Packaging: Blister packs of 4, 8, or 12 tablets
• Excipients: Microcrystalline cellulose, pregelatinized starch, magnesium stearate, hypromellose
• Manufactured under cGMP (current Good Manufacturing Practices) standards
• Shelf life: 36 months from date of manufacture

Benefits

• Effectively eliminates a broad spectrum of parasitic organisms, including Strongyloides stercoralis and Onchocerca volvulus
• Reduces transmission of parasitic diseases in endemic communities
• Single or short-course dosing regimen supports high patient adherence
• Low incidence of severe adverse effects when used according to guidelines
• Contributes to decreased morbidity associated with chronic parasitic infections
• Helps prevent complications such as skin and ocular damage in onchocerciasis

Common use

Iversun is primarily indicated for the treatment of strongyloidiasis (caused by the nematode Strongyloides stercoralis) and onchocerciasis (river blindness, caused by Onchocerca volvulus). It may also be used off-label under specialist supervision for other parasitic infections, including scabies and certain ectoparasitic infestations. Its use is generally reserved for confirmed diagnoses through stool examination, skin snip tests, or serological evidence, depending on the suspected parasite.

Dosage and direction

Dosage is weight-based and must be calculated by a healthcare provider. For strongyloidiasis, the typical dose is 200 mcg/kg orally as a single dose. For onchocerciasis, the standard dose is 150 mcg/kg orally as a single dose, which may be repeated every 6–12 months depending on clinical presentation and endemic setting. Tablets should be taken with a full glass of water on an empty stomach, at least 1 hour before a meal. Do not crush or split tablets.

Precautions

Use with caution in elderly patients, or those with hepatic impairment. Breastfeeding should be suspended during treatment, as ivermectin is excreted in human milk. Avoid alcohol consumption during treatment. Patients should be advised that rapid killing of parasites may lead to an inflammatory response (Mazzotti-like reaction), which may require symptomatic management. Not recommended during pregnancy unless potential benefit justifies potential risk.

Contraindications

Hypersensitivity to ivermectin or any component of the formulation. Contraindicated in patients with history of severe central nervous system adverse reactions to previous ivermectin treatment. Not for use in children weighing less than 15 kg.

Possible side effect

Common side effects may include dizziness, pruritus, fever, rash, and joint pain. Less frequently, diarrhea, nausea, orthostatic hypotension, or elevated liver enzymes may occur. In cases of heavy parasitic load, a systemic reaction (Mazzotti reaction) may present with arthralgia, lymph node tenderness, and ocular irritation. Severe but rare adverse effects include hepatitis or Stevens-JJohnson syndrome.

Drug interaction

Iversun may interact with other drugs that increase blood-brain barrier permeability (e.g., certain antifungals, antibiotics). Concurrent use with warfarin may potentiate anticoagulant effects. Use with CNS depressants may enhance sedative effects. Caution is advised when co-administered with CYP3A4 inhibitors (e.g., ketoconazole).

Missed dose

If a dose is missed, take it as soon as remembered unless it is almost time for the next dose. Do not double the dose. In most cases, Iversun is administered as a single dose, so missed dosing is unlikely in standard treatment courses.

Overdose

Symptoms may include nausea, vomiting, diarrhea, dizziness, and pupillary dilation. In severe cases, hypotension and respiratory depression may occur. There is no specific antidote; treatment is supportive and symptomatic. Gastric lavage may be considered if ingestion was recent.

Storage

Store below 30°C (86°F) in a dry place, protected from light. Keep in original blister packaging until use. Keep out of reach of children and pets.

Disclaimer

Iversun is a prescription medication and should be used only under the supervision of a qualified healthcare professional. This information is for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always follow the guidance of your prescribing physician.

Reviews

“As an infectious disease specialist working in endemic regions, I have found Iversun to be a reliable and well-tolerated option for managing strongyloidiasis. The single-dose regimen greatly improves compliance.” — Dr. Elena M., MD
“Effective and straightforward. My patients appreciate the minimal side effects compared to some older antiparasitics.” — Clinical Pharmacist, West Africa Regional Health Service
“Used Iversun for chronic scabies under dermatological guidance—clearance was achieved without recurrence. Would recommend under professional supervision.” — Patient T., verified user